Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The experience of fatigue varies considerably between individuals taking GLP-1 receptor agonists
Powder gives you flexibility and consistent dosing
Silvana Obici, an endocrinologist and chief of the division of endocrinology at Stony Brook Medicine
Retatrutide (development code LY3437943) is an investigational injectable medicine developed by Eli Lilly and Company, currently under clinical evaluation for the treatment of obesity and type 2 diabetes
Published by the iPharma Research Team Medically reviewed by PCCA- and NHIA-certified compounding pharmacists with 27+ years of clinical experience in sterile compounding, GLP-1 therapy, and personalized medicine Last reviewed July 2026 Educational information only
US$ 21.06
US$ 26.55
US$ 20.06
